Diligence memo · auto-generated · as of July 2, 2026
ImmuVen, Inc.
ImmuVen, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
ImmuVen, Inc. operates in Biotechnology, based in CHAMPAIGN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
ImmuVen, Inc. has raised $710K in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $255K on 2009-06-22.
Most recent recorded round closed around 2009-06-22.
Valuation (modeled)modeled
Provath models ImmuVen, Inc. at approximately $14M (range $136K–$160M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.51× the median modeled value of Pre-Seed Biotechnology companies in 2007–2009 (62 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 17.0 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 14% of Biotechnology peers (4293 compared).
Modeled value ranks above 23% of those peers.
Closest niche peers: Cellay, Inc., Cellutions Inc, Atherotech, Inc., Bio-Tree Systems, Inc., Theocorp Holding Company, LLC.
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.